Cellectis sets date for 2025 earnings release

Cellectis S.A. filed a report stating it will release its fourth quarter and full year 2025 financial results on March 19, 2026, after the U.S. market close.

Accepted by SEC EDGAR 03/12/2026 - 04:35 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Cellectis S.A. filed a report stating it will release its fourth quarter and full year 2025 financial results on March 19, 2026, after the U.S. market close. An investor conference call and webcast will follow on March 20, 2026, at 8:00 AM ET / 1:00 PM CET to discuss the results and provide a business update.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cellectis (CLLS) report its Q4 and full-year 2025 results?

Cellectis will report its fourth quarter and full-year 2025 results on March 19, 2026, after the U.S. market close. The announcement will cover financial performance for the period ended December 31, 2025, and precedes a scheduled investor conference call.

When is Cellectis (CLLS) hosting the Q4 and FY 2025 earnings call?

Cellectis will host its earnings conference call on March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will review fourth quarter and full-year 2025 results and include an update on the company’s business activities and pipeline development.

How can investors access the Cellectis (CLLS) Q4 and FY 2025 earnings webcast?

Investors can access the webcast through the provided online link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f. The webcast will run alongside the March 20, 2026 conference call covering the company’s 2025 financial results and business update.

What dial-in numbers are available for the Cellectis (CLLS) earnings call?

Domestic participants can dial +1-800-579-2543, while international callers can use +1-785-424-1789, with Conference ID: CLLSFY. These numbers connect investors to the March 20, 2026 call discussing fourth quarter and full-year 2025 performance and activities.

What type of company is Cellectis (CLLS)?

Cellectis is a clinical-stage biotechnology company using a gene-editing platform to develop cell and gene therapies. It focuses on allogeneic CAR T immunotherapies and other gene therapy indications, with headquarters in Paris and additional locations in New York and Raleigh, NC.

On which exchanges are Cellectis (CLLS) shares listed?

Cellectis shares trade on the Nasdaq Global Market under ticker CLLS and on Euronext Growth under ticker ALCLS. These listings provide access for U.S. and European investors to the clinical-stage gene-editing and cell therapy company’s equity.

Who should investors contact for Cellectis (CLLS) investor relations questions?

Investor relations inquiries should be directed to Arthur Stril, Chief Financial Officer and Chief Business Officer, via investors@cellectis.com. This contact can provide information around financial communications, including the upcoming fourth quarter and full-year 2025 results and related materials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: March 12, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Translation of registrant's name into English)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

EXHIBIT INDEX

Exhibit		Title

99.1		Press Release dated March 12, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Cellectis S.A.
		(Registrant)


Date: March 12, 2026		/s/ André Choulika
		André Choulika
		Chief Executive Officer

EXHIBIT 99.1

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows:

Dial in information:

Domestic: +1-800-579-2543
International: +1-785-424-1789
Conference ID: CLLSFY
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

20260312_FY 2025 earnings call announcement_ENGLISH.pdf (https://ml.globenewswire.com/Resource/Download/20075d8b-24bd-4666-a8d4-ee89d079068b)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 PRESS RELEASE 3.4 KB